These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8101011)

  • 1. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials.
    Lin DY; Fischl MA; Schoenfeld DA
    Stat Med; 1993 May; 12(9):835-42. PubMed ID: 8101011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of large, simple trials in the evaluation of AIDS treatment strategies.
    Ellenberg SS; Foulkes MA
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):405-15. PubMed ID: 7912842
    [No Abstract]   [Full Text] [Related]  

  • 3. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex.
    De Gruttola V; Wulfsohn M; Fischl MA; Tsiatis A
    J Acquir Immune Defic Syndr (1988); 1993 Apr; 6(4):359-65. PubMed ID: 8095980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.
    Choi S; Lagakos SW; Schooley RT; Volberding PA
    Ann Intern Med; 1993 May; 118(9):674-80. PubMed ID: 8096373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population dynamics of HIV within an individual after treatment with zidovudine.
    McLean AR; Emery VC; Webster A; Griffiths PD
    AIDS; 1991 May; 5(5):485-9. PubMed ID: 1677807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC; Martin ES
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate markers in AIDS and cancer trials.
    Fleming TR
    Stat Med; 1994 Jul 15-30; 13(13-14):1423-35; discussion 1437-40. PubMed ID: 7973222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 counts as surrogate markers for progression to AIDS.
    Harris PJ
    Ann Intern Med; 1994 Jan; 120(1):88. PubMed ID: 7902690
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical effectiveness of zidovudine].
    Mulder JW
    Ned Tijdschr Geneeskd; 1995 Feb; 139(5):211-3. PubMed ID: 7854480
    [No Abstract]   [Full Text] [Related]  

  • 12. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zidovudine in asymptomatic HIV infection.
    Berger PB
    N Engl J Med; 1993 Dec; 329(25):1895; author reply 1895-6. PubMed ID: 7902534
    [No Abstract]   [Full Text] [Related]  

  • 14. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Moore RD; Keruly J; Richman DD; Creagh-Kirk T; Chaisson RE
    AIDS; 1992 Jul; 6(7):671-7. PubMed ID: 1503686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
    N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
    Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of zidovudine dosing.
    Stoukides CA; Cichocki TJ
    Ann Pharmacother; 1992 Jun; 26(6):784-5. PubMed ID: 1351766
    [No Abstract]   [Full Text] [Related]  

  • 18. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.
    Levacher M; Tallet S; Dazza MC; Dournon E; Rouveix B; Pocidalo JJ
    Clin Exp Immunol; 1990 Aug; 81(2):177-82. PubMed ID: 1696859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trend towards decreased survival in patients infected with HIV resistant to zidovudine.
    Gøtzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF
    Scand J Infect Dis; 1992; 24(5):563-5. PubMed ID: 1361240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy.
    Pluda JM; Yarchoan R; Jaffe ES; Feuerstein IM; Solomon D; Steinberg SM; Wyvill KM; Raubitschek A; Katz D; Broder S
    Ann Intern Med; 1990 Aug; 113(4):276-82. PubMed ID: 1973886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.